# Dual gene deletion improves engineered T cells in tumour models

_Published Thursday, November 5, 2026 at 1:36 PM EST · Science · Latest · Tier 2 — Notable_

Researchers reporting in Nature found that deleting both NR4A1 and SOCS3 improved engineered T cells' antitumour performance across different tumour models. The combination outperformed several benchmark modifications involving one or two genes in T cells and CAR-T cells, which are engineered to recognize cancer targets.

The team identified the pair through a high-throughput screen that tested two gene deletions together in living organisms. The modified cells showed higher metabolic fitness and mitochondrial activity, alongside long-term tumour control without compromising the safety features assessed.

The findings establish a preclinical engineering approach rather than clinical efficacy. Yale University has filed a patent application.

## Sources

- [Nature](https://www.nature.com/articles/s41586-026-10956-z)

---
Canonical: https://techandbusiness.org/newswire/OER64a8PXnfgzQxBKTepen
Published: 2026-11-05T18:36:26.761Z
Story chronology: 2026-11-04T00:00:00.000Z
Retrieved: 2026-11-06T22:51:14.432Z
Publisher: Tech & Business (techandbusiness.org)